WEBULL
News
INO
1.810
+4.62%
0.080
Inovio Faces Shareholder Class Action Over CELLECTRA Manufacturing Claims
Reuters · 8h ago
Inovio Shareholders Face April 7 Deadline in Securities Fraud Class Action
Reuters · 11h ago
Weekly Report: what happened at INO last week (0216-0220)?
Weekly Report · 19h ago
Rosen Law Firm Urges Inovio Investors to Meet April 7 Lead Plaintiff Deadline in Securities Class Action
Reuters · 1d ago
Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Barchart · 3d ago
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
PR Newswire · 4d ago
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
Reuters · 4d ago
Inovio Investors Face April 7, 2026 Lead Plaintiff Deadline in Securities Class Action
Reuters · 4d ago
Deadline Approaching: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Barchart · 4d ago
Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact The Gross Law Firm
Barchart · 4d ago
Gross Law Firm Files Securities Class Action Against Inovio Pharmaceuticals (INO)
Reuters · 5d ago
Law Offices of Frank R. Cruz Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 5d ago
Inovio Pharmaceuticals Faces Class Action Over Delayed FDA Submission
Reuters · 6d ago
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders to Inquire About Securities Fraud Class Action
Barchart · 6d ago
Inovio Faces Securities Class Action Over Alleged Misleading Statements
Reuters · 02/16 14:02
Weekly Report: what happened at INO last week (0209-0213)?
Weekly Report · 02/16 09:50
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Alleged Misleading Statements
Reuters · 02/14 17:11
Inovio Pharmaceuticals Faces Securities Class Action Over Alleged Misleading Statements
Reuters · 02/14 12:33
Inovio Pharmaceuticals Faces Securities Fraud Class Action Over Alleged Misleading Statements
Reuters · 02/13 20:03
Law Offices of Howard G. Smith Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders To Inquire About Securities Fraud Class Action
Barchart · 02/13 11:29
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.